The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells

Tomoyuki Nakamura, Kazuhiro Tanaka, Tomoya Matsunobu, Takamitsu Okada, Fumihiko Nakatani, Riku Sakimura, Masuo Hanada, Yukihide Iwamoto

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

EWS-Fli1 plays important roles in oncogenesis of Ewing's family tumors (EFTs). We have reported that EWS-Fli1 inhibits p21waf1/cip1 and p27kip1 expressions, which are degraded by the ubiquitin-proteasome pathway. Bortezomib efficiently up-regulated p21waf1/cip1 and p27kip1 expression, and induced apoptosis accompanied by the expression of cleaved-PARP, DR4 and activated caspase-8 in EFT cells. Since most EFTs deaths result from the tumor being resistant to chemotherapeutic drugs, the effects of novel anti-tumor reagents on drug-resistant tumors were next investigated. The results demonstrated that the drug-resistant EFT clones were cross-resistant to bortezomib probably due to the overexpression of the efflux pumps, P-glycoprotein and MRP1. We further investigated whether the efflux pump inhibitors would modulate the effects of bortezomib. The combination of P-gp-specific or MRP1-specific inhibitors could enhance the anti-tumor effects of bortezomib on the drug-resistant clones. These data suggest that bortezomib might be a substrate of P-gp and MRP1. Although bortezomib would be effective on the primary EFTs, it is necessary to pay attention to the resistance to bortezomib in clinical trials for the advanced cases. The combination of bortezomib and the efflux pump inhibitors might be a promising method as a novel molecular target therapy for advanced EFTs.

Original languageEnglish
Pages (from-to)803-811
Number of pages9
JournalInternational journal of oncology
Volume31
Issue number4
Publication statusPublished - Oct 1 2007

Fingerprint

Proteasome Inhibitors
Ewing's Sarcoma
Pharmaceutical Preparations
Neoplasms
Clone Cells
Bortezomib
Caspase 8
P-Glycoprotein
Proteasome Endopeptidase Complex
Ubiquitin
Carcinogenesis
Clinical Trials
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakamura, T., Tanaka, K., Matsunobu, T., Okada, T., Nakatani, F., Sakimura, R., ... Iwamoto, Y. (2007). The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. International journal of oncology, 31(4), 803-811.

The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. / Nakamura, Tomoyuki; Tanaka, Kazuhiro; Matsunobu, Tomoya; Okada, Takamitsu; Nakatani, Fumihiko; Sakimura, Riku; Hanada, Masuo; Iwamoto, Yukihide.

In: International journal of oncology, Vol. 31, No. 4, 01.10.2007, p. 803-811.

Research output: Contribution to journalArticle

Nakamura, T, Tanaka, K, Matsunobu, T, Okada, T, Nakatani, F, Sakimura, R, Hanada, M & Iwamoto, Y 2007, 'The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells', International journal of oncology, vol. 31, no. 4, pp. 803-811.
Nakamura, Tomoyuki ; Tanaka, Kazuhiro ; Matsunobu, Tomoya ; Okada, Takamitsu ; Nakatani, Fumihiko ; Sakimura, Riku ; Hanada, Masuo ; Iwamoto, Yukihide. / The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. In: International journal of oncology. 2007 ; Vol. 31, No. 4. pp. 803-811.
@article{2834d6d82a314ad3a5f7111617e71347,
title = "The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells",
abstract = "EWS-Fli1 plays important roles in oncogenesis of Ewing's family tumors (EFTs). We have reported that EWS-Fli1 inhibits p21waf1/cip1 and p27kip1 expressions, which are degraded by the ubiquitin-proteasome pathway. Bortezomib efficiently up-regulated p21waf1/cip1 and p27kip1 expression, and induced apoptosis accompanied by the expression of cleaved-PARP, DR4 and activated caspase-8 in EFT cells. Since most EFTs deaths result from the tumor being resistant to chemotherapeutic drugs, the effects of novel anti-tumor reagents on drug-resistant tumors were next investigated. The results demonstrated that the drug-resistant EFT clones were cross-resistant to bortezomib probably due to the overexpression of the efflux pumps, P-glycoprotein and MRP1. We further investigated whether the efflux pump inhibitors would modulate the effects of bortezomib. The combination of P-gp-specific or MRP1-specific inhibitors could enhance the anti-tumor effects of bortezomib on the drug-resistant clones. These data suggest that bortezomib might be a substrate of P-gp and MRP1. Although bortezomib would be effective on the primary EFTs, it is necessary to pay attention to the resistance to bortezomib in clinical trials for the advanced cases. The combination of bortezomib and the efflux pump inhibitors might be a promising method as a novel molecular target therapy for advanced EFTs.",
author = "Tomoyuki Nakamura and Kazuhiro Tanaka and Tomoya Matsunobu and Takamitsu Okada and Fumihiko Nakatani and Riku Sakimura and Masuo Hanada and Yukihide Iwamoto",
year = "2007",
month = "10",
day = "1",
language = "English",
volume = "31",
pages = "803--811",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells

AU - Nakamura, Tomoyuki

AU - Tanaka, Kazuhiro

AU - Matsunobu, Tomoya

AU - Okada, Takamitsu

AU - Nakatani, Fumihiko

AU - Sakimura, Riku

AU - Hanada, Masuo

AU - Iwamoto, Yukihide

PY - 2007/10/1

Y1 - 2007/10/1

N2 - EWS-Fli1 plays important roles in oncogenesis of Ewing's family tumors (EFTs). We have reported that EWS-Fli1 inhibits p21waf1/cip1 and p27kip1 expressions, which are degraded by the ubiquitin-proteasome pathway. Bortezomib efficiently up-regulated p21waf1/cip1 and p27kip1 expression, and induced apoptosis accompanied by the expression of cleaved-PARP, DR4 and activated caspase-8 in EFT cells. Since most EFTs deaths result from the tumor being resistant to chemotherapeutic drugs, the effects of novel anti-tumor reagents on drug-resistant tumors were next investigated. The results demonstrated that the drug-resistant EFT clones were cross-resistant to bortezomib probably due to the overexpression of the efflux pumps, P-glycoprotein and MRP1. We further investigated whether the efflux pump inhibitors would modulate the effects of bortezomib. The combination of P-gp-specific or MRP1-specific inhibitors could enhance the anti-tumor effects of bortezomib on the drug-resistant clones. These data suggest that bortezomib might be a substrate of P-gp and MRP1. Although bortezomib would be effective on the primary EFTs, it is necessary to pay attention to the resistance to bortezomib in clinical trials for the advanced cases. The combination of bortezomib and the efflux pump inhibitors might be a promising method as a novel molecular target therapy for advanced EFTs.

AB - EWS-Fli1 plays important roles in oncogenesis of Ewing's family tumors (EFTs). We have reported that EWS-Fli1 inhibits p21waf1/cip1 and p27kip1 expressions, which are degraded by the ubiquitin-proteasome pathway. Bortezomib efficiently up-regulated p21waf1/cip1 and p27kip1 expression, and induced apoptosis accompanied by the expression of cleaved-PARP, DR4 and activated caspase-8 in EFT cells. Since most EFTs deaths result from the tumor being resistant to chemotherapeutic drugs, the effects of novel anti-tumor reagents on drug-resistant tumors were next investigated. The results demonstrated that the drug-resistant EFT clones were cross-resistant to bortezomib probably due to the overexpression of the efflux pumps, P-glycoprotein and MRP1. We further investigated whether the efflux pump inhibitors would modulate the effects of bortezomib. The combination of P-gp-specific or MRP1-specific inhibitors could enhance the anti-tumor effects of bortezomib on the drug-resistant clones. These data suggest that bortezomib might be a substrate of P-gp and MRP1. Although bortezomib would be effective on the primary EFTs, it is necessary to pay attention to the resistance to bortezomib in clinical trials for the advanced cases. The combination of bortezomib and the efflux pump inhibitors might be a promising method as a novel molecular target therapy for advanced EFTs.

UR - http://www.scopus.com/inward/record.url?scp=35848931009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848931009&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 803

EP - 811

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -